Clinical Trial Detail

NCT ID NCT03674112
Title A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Hoffmann-La Roche

Her2-receptor positive breast cancer


Pertuzumab + Trastuzumab

Age Groups: senior adult

Additional content available in CKB BOOST